Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 27,500 | |||
5 mg | 在庫あり | ¥ 66,500 | |||
10 mg | 在庫あり | ¥ 110,000 | |||
25 mg | 在庫あり | ¥ 192,500 | |||
50 mg | 在庫あり | ¥ 266,500 | |||
100 mg | 在庫あり | ¥ 358,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 73,000 |
説明 | ZT-1a is a SPAK inhibitor.ZT-1a inhibits SPAK.ZT-1a can be used for the prevention and treatment of neurodegenerative and neurocognitive disorders. |
In vitro |
ZT-1a inhibits the Na-K-2Cl cotransporter (NKCC1) and stimulates the K-Cl cotransporter (KCC) by reducing its SPS1-related proline/alanine-rich kinase (SPAK) dependent phosphorylation[1].At 1 μM ZT-1a, NKCC1 p-Thr203/207/212 phosphorylation is inhibited by 72±5.2%, and in HEK-293 cells, KCC phosphorylation at sites 1/2 is inhibited by 65-77% at 3 μM ZT-1a[1].Phosphorylation of SPAK at the Ser373 site is inhibited by 70±3.8% at 3-10 μM ZT-1a[2]. ZT-1a (10 μM) inhibits NKCC1 but stimulates KCC3 activity[2]. |
In vivo | ZT-1a inhibits the SPAK-dependent upregulation of NKCC1 and KCC3 phosphorylation in ischemic brains.post-stroke treatment with ZT-1a protects both gray and white matter tissues in ischemic brains[1]. |
分子量 | 445.73 |
分子式 | C22H15Cl3N2O2 |
CAS No. | 212135-62-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL(179.48 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZT-1a 212135-62-1 Others ZT 1a ZT1a Inhibitor inhibitor inhibit